Humedix Selected for Excellent Enterprise Research Institute Development Project

[Asia Economy Reporter Chunhee Lee] Humedix announced on the 31st that its project titled "Development of production technology for high molecular weight medical polynucleotide (PN) with an average molecular weight of over 1000 kDa and development of osteoarthritis injection and wound dressing application products" has been selected for the 2022 Excellent Enterprise Research Institute Promotion Project (ATC+) organized by the Ministry of Trade, Industry and Energy.

ATC+ is a support program aimed at fostering affiliated research institutes of small and medium-sized enterprises as key players in industrial innovation through research and development (R&D) support, thereby enhancing national technological competitiveness.

Accordingly, Humedix will receive over 2 billion KRW in government funding from the Ministry of Trade, Industry and Energy over the next four years. Through this, the company plans to promote the localization of medical PN production technology, which currently depends on imports, and develop composite joint injection agents and wound dressings using PN. Joint research with the Catholic University Medical School will also be conducted to clarify the optimized efficacy and effectiveness of the products.

A Humedix official stated, "As the government has recognized Humedix's PN technology and competitiveness, we plan to devote all efforts to developing PN localization technology," adding, "We will subsequently develop various products utilizing PN to contribute to national economic development and the improvement of public health."

This content was produced with the assistance of AI translation services.